×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:SBBP

Strongbridge Biopharma Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$1.95
$2.06
50-Day Range
$1.89
$2.29
52-Week Range
$1.85
$4.26
Volume
684,684 shs
Average Volume
866,464 shs
Market Capitalization
$135.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Receive SBBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SBBP Stock Forecast (MarketRank)

Overall MarketRank

0.97 out of 5 stars

Medical Sector

1263rd out of 1,418 stocks

Pharmaceutical Preparations Industry

624th out of 679 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
Strongbridge Biopharma logo

About Strongbridge Biopharma (NASDAQ:SBBP)

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

SBBP Stock News Headlines

Tudor Capital Europe LLP : Form 8.3 - Strongbridge Biopharma Plc
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SBBP
Fax
N/A
Employees
72
Year Founded
N/A

Company Calendar

Last Earnings
8/05/2021
Today
6/24/2022

Profitability

Net Income
$-45.08 million
Net Margins
-115.67%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$30.73 million
Book Value
$0.98 per share

Miscellaneous

Free Float
N/A
Market Cap
$135.66 million
Optionable
Optionable
Beta
1.58














Strongbridge Biopharma Frequently Asked Questions

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) issued its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09. The biotechnology company had revenue of $10.04 million for the quarter, compared to analyst estimates of $8.83 million. Strongbridge Biopharma had a negative trailing twelve-month return on equity of 66.82% and a negative net margin of 115.67%.
View Strongbridge Biopharma's earnings history
.

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the following people:
  • John H. Johnson, Chief Executive Officer & Director
  • Richard S. Kollender, President & Chief Financial Officer
  • Fredric Cohen, Chief Medical Officer
  • Brian Conner, Chief Compliance Officer
  • Peter J. Valentinsson, Senior Vice President-Global Technical Operations

What other stocks do shareholders of Strongbridge Biopharma own?

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.00.

How much money does Strongbridge Biopharma make?

Strongbridge Biopharma (NASDAQ:SBBP) has a market capitalization of $135.66 million and generates $30.73 million in revenue each year. The biotechnology company earns $-45.08 million in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Strongbridge Biopharma have?

Strongbridge Biopharma employs 72 workers across the globe.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The official website for Strongbridge Biopharma is www.strongbridgebio.com. The biotechnology company can be reached via phone at (610) 254-9200 or via email at [email protected].

This page (NASDAQ:SBBP) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.